[Response of healthy subjects to plasma-derived anti-hepatitis B vaccine].
71 healthy individuals were vaccinated against hepatitis B virus. Each person received 60 mcgrs of HBsAg derived from chronic carriers heat-formalin treated plasma. All the vaccinees were tested for anti-HBs and 94.4% of them reached the protective titer (greater than 10 mUI/ml). There were few and no significant side effects (15.4%). Those vaccines with antibody titers higher than 100 mUI/ml were significantly younger than those with antibody titers lower than 100 mUI/ml. There was no significant difference between the body surface means of both groups. Thus, the vaccine level response is not associated with the body surface but with people's age.
Curciarello
J O
JO
Cátedra D de Medicina Interna, Facultad de Ciencias Médicas, U.N.L.P., Argentina.
Echeverría
R F
RF
Jmelnitzky
A
A
Chiera
A
A
Bolzan
H
H
Pérez
C
C
Corallini
O
O
D000328:Adult; D000367:Age Factors; D001830:Body Surface Area; D005260:Female; D006510:Hepatitis B Antibodies / Q000032:analysis / Q000276:immunology*; D006514:Hepatitis B Surface Antigens / Q000008:administration & dosage / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D006514:Hepatitis B Surface Antigens; D014761:Viral Hepatitis Vaccines
Respuesta de sujetos sanos a la vacuna anti-hepatitis B plasmo-derivada.